TFF Pharmaceuticals (TFFP)
(Delayed Data from NSDQ)
$2.92 USD
-0.13 (-4.21%)
Updated Apr 26, 2024 03:58 PM ET
After-Market: $2.89 -0.03 (-1.08%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Brokerage Reports
0 items in cart
TFF Pharmaceuticals, Inc. [TFFP]
Reports for Purchase
Showing records 1 - 20 ( 148 total )
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive TFF TAC Biomarker Data Shown at ISHLT, Lower Systemic Exposure
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q23: TFF TAC Data Support Phase 3 Trial, Looking To Outlicense TFF VORI
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
New TFF TAC Data Supports Phase 3 Trial, Looking To Outlicense TFF VORI
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - 36th Annual Roth Conference, Biotechnology Track, March 17-19
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive Preliminary Phase 2 TFF VORI TFF TAC Results, Trials Continue
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q23: Funded Beyond Release Of Potentially Transformational Phase 2 Data
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare: HC Opportunities Conference in NYC on October 12th
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q23: Funded Beyond Release Of Potentially Transformational Phase 2 Data
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Opens TFF VORI Expanded Access Program With Uniphar Durbin Ireland Ltd.
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Receives Validating $3 Million SBIR Grant For Universal Influenza Vaccine
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
POC Phase 2 Data Still on Track for YE23; Reiterate Buy Rating; Adjusting PT to $4
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q23: Renewed Focus With New Management, TFF VORI TFF TAC Data in 2023
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Signs CRADA with NIEHS for Dry Powder Hyaluronan for Respiratory Diseases
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J